Severity of Reactions Linked to Stopping Oral Immunotherapy
Patients with food allergy who discontinued oral immunotherapy were those who were more likely to experience a reaction to the treatment than those who reached maintenance of allergen foods, according to research at the Pediatric Academic Societies 2025 Meeting.
They were also more likely to experience moderate and severe reactions, particularly mild abdominal pain, vomiting, diarrhea, and pruritus, reported Eirene Fithian, of the MD program at Weill Cornell Medical College in New York City, and colleagues in a poster.
'Oral immunotherapy discontinuation was low overall but varied by allergen, with higher discontinuation rates observed for allergens with a high incidence of severe reactions compared to the mean,' they reported.
Food allergy affects an estimated 8% of children and 10% of adults in the United States, but advances in oral immunotherapy have opened up treatment options for these individuals, the researchers noted.
'The fear of adverse reactions remains a barrier to treatment, yet little data exists on the role of adverse reactions in treatment discontinuation,' they wrote. 'Identifying factors associated with oral immunotherapy discontinuation is critical to addressing concerns and improving the safety and efficacy of oral immunotherapy.'
The researchers conducted a retrospective cohort study with data from 1003 patients, aged less than 1 year to 47 years, who underwent oral immunotherapy for peanut, tree nut, milk, egg, and/or sesame allergy at Latitude Food Allergy Care between 2018 and 2024. They assessed all treatment-related reactions in terms of frequency, type, and severity. They excluded patients lost to follow-up or updosing and stratified the remaining patients by those who discontinued treatment vs those who reached maintenance for all foods.
Those who discontinued treatment included 8.2% receiving oral immunotherapy for milk, 7.3% for sesame, 6.1% for egg, 5.2% for tree nut, and 5.1% for peanut. The overall discontinuation rate was 5%. (Some patients were receiving oral immunotherapy for multiple allergens, so there is overlap by allergen discontinuation rates.)
After adjusting for gender, age, and comorbidities, results revealed that patients undergoing oral immunotherapy for milk had more than twice the odds of discontinuing treatment (OR, 2.68; P < .05). The average incidence of severe reactions was 13%, but incidence was higher for milk (22%), sesame (20%), and egg (25%).
About 1 in 5 patients (20%) who discontinued therapy had any reaction compared with 5.2% overall and 4.0% of those who reached maintenance.
'Patients who discontinued oral immunotherapy had similar frequencies of experiencing mild reactions compared to those who reached maintenance but a higher incidence of moderate and severe reactions,' the researchers reported. Those who discontinued treatment also 'had a higher frequency of reactions to oral immunotherapy doses, including higher frequency of the top three reported symptoms of reaction: Mild abdominal pain, emesis or diarrhea, and pruritus compared to the overall mean of those who reached maintenance.'
Mild abdominal pain was reported in 5.5% of those who discontinued compared with 1.3% overall and 0.9% of those who reached maintenance. Vomiting or diarrhea occurred in 4.5% of those who discontinued treatment compared with 0.4% overall and 0.3% who reached maintenance. Pruritus occurred in 4.9% of those who discontinued compared with 2.1% overall and 1.9% of those who reached maintenance.
'The number of patients is very impressive and adds to the strengths of this retrospective study,' Jonathan Tam, MD, medical director of the Gores Family Allergy Center at Children's Hospital Los Angeles, Los Angeles, told Medscape Medical News . He also noted that the rate of patients who discontinued oral immunotherapy overall was lower than published rates in clinical trials, but the rate of severe reactions was conversely higher.
'Even given this rate of severe reactions, the discontinuation rate was generally low,' Tam said. 'Overall, the findings make sense and are a practical guide to helping patients make decisions oral immunotherapy.'
The authors did not report receiving external funding or having any disclosures. Tam was not involved with the study but is working with Latitude in a Children's Hospital of Los Angeles clinic.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
05-05-2025
- Medscape
Severity of Reactions Linked to Stopping Oral Immunotherapy
Patients with food allergy who discontinued oral immunotherapy were those who were more likely to experience a reaction to the treatment than those who reached maintenance of allergen foods, according to research at the Pediatric Academic Societies 2025 Meeting. They were also more likely to experience moderate and severe reactions, particularly mild abdominal pain, vomiting, diarrhea, and pruritus, reported Eirene Fithian, of the MD program at Weill Cornell Medical College in New York City, and colleagues in a poster. 'Oral immunotherapy discontinuation was low overall but varied by allergen, with higher discontinuation rates observed for allergens with a high incidence of severe reactions compared to the mean,' they reported. Food allergy affects an estimated 8% of children and 10% of adults in the United States, but advances in oral immunotherapy have opened up treatment options for these individuals, the researchers noted. 'The fear of adverse reactions remains a barrier to treatment, yet little data exists on the role of adverse reactions in treatment discontinuation,' they wrote. 'Identifying factors associated with oral immunotherapy discontinuation is critical to addressing concerns and improving the safety and efficacy of oral immunotherapy.' The researchers conducted a retrospective cohort study with data from 1003 patients, aged less than 1 year to 47 years, who underwent oral immunotherapy for peanut, tree nut, milk, egg, and/or sesame allergy at Latitude Food Allergy Care between 2018 and 2024. They assessed all treatment-related reactions in terms of frequency, type, and severity. They excluded patients lost to follow-up or updosing and stratified the remaining patients by those who discontinued treatment vs those who reached maintenance for all foods. Those who discontinued treatment included 8.2% receiving oral immunotherapy for milk, 7.3% for sesame, 6.1% for egg, 5.2% for tree nut, and 5.1% for peanut. The overall discontinuation rate was 5%. (Some patients were receiving oral immunotherapy for multiple allergens, so there is overlap by allergen discontinuation rates.) After adjusting for gender, age, and comorbidities, results revealed that patients undergoing oral immunotherapy for milk had more than twice the odds of discontinuing treatment (OR, 2.68; P < .05). The average incidence of severe reactions was 13%, but incidence was higher for milk (22%), sesame (20%), and egg (25%). About 1 in 5 patients (20%) who discontinued therapy had any reaction compared with 5.2% overall and 4.0% of those who reached maintenance. 'Patients who discontinued oral immunotherapy had similar frequencies of experiencing mild reactions compared to those who reached maintenance but a higher incidence of moderate and severe reactions,' the researchers reported. Those who discontinued treatment also 'had a higher frequency of reactions to oral immunotherapy doses, including higher frequency of the top three reported symptoms of reaction: Mild abdominal pain, emesis or diarrhea, and pruritus compared to the overall mean of those who reached maintenance.' Mild abdominal pain was reported in 5.5% of those who discontinued compared with 1.3% overall and 0.9% of those who reached maintenance. Vomiting or diarrhea occurred in 4.5% of those who discontinued treatment compared with 0.4% overall and 0.3% who reached maintenance. Pruritus occurred in 4.9% of those who discontinued compared with 2.1% overall and 1.9% of those who reached maintenance. 'The number of patients is very impressive and adds to the strengths of this retrospective study,' Jonathan Tam, MD, medical director of the Gores Family Allergy Center at Children's Hospital Los Angeles, Los Angeles, told Medscape Medical News . He also noted that the rate of patients who discontinued oral immunotherapy overall was lower than published rates in clinical trials, but the rate of severe reactions was conversely higher. 'Even given this rate of severe reactions, the discontinuation rate was generally low,' Tam said. 'Overall, the findings make sense and are a practical guide to helping patients make decisions oral immunotherapy.' The authors did not report receiving external funding or having any disclosures. Tam was not involved with the study but is working with Latitude in a Children's Hospital of Los Angeles clinic.
Boston Globe
28-11-2024
- Boston Globe
How will Trump's COVID contrarians handle the next pandemic?
Get Starting Point A guide through the most important stories of the morning, delivered Monday, Wednesday, and Friday. Enter Email Sign Up Dr. David Weldon, a Republican former Congress member who is Trump's choice to lead the Centers for Disease Control and Prevention, has espoused the debunked theory that thimerosal, a mercury compound in certain vaccines, causes autism. As a Congress member, he introduced legislation that would strip the CDC of its role in ensuring vaccine safety, saying the agency had a 'conflict of interest' because it also promotes vaccination. Related : Advertisement And Dr. Mehmet Oz, the talk show host who has been picked by Trump to run Medicare and Medicaid, prodded officials in the first Trump administration to give emergency authorization for the malaria drug hydroxychloroquine to treat COVID-19. The FDA later revoked the authorization when studies showed the drug carried risks, including serious heart issues, to coronavirus patients. 'If the worst-case scenario happens and we have a serious public health crisis, the body count is going to be enormous because these guys don't have the skills or the will to do anything about it,' said John P. Moore, a virus expert and professor at Cornell University's Weill Cornell Medical College. None of Trump's picks have deep expertise in infectious disease, and each will have to be confirmed by the Senate. 'At the end of the day, if they are confirmed, we are going to have to figure out a way to work with them,' said Dr. Carlos del Rio, an infectious disease expert at Emory University. Advertisement Trump's own commitment to pandemic preparedness is unclear. During his first administration, he dismantled a White House office that had been set up by his predecessor, President Barack Obama, to deal with emerging global health threats. Last year, President Joe Biden created a White House Office of Pandemic Preparedness, which Trump cannot abandon because Congress mandated it by legislation in 2022. There is no way, of course, to predict the arrival of the next pandemic. At the outset of the coronavirus pandemic, experts called it the worst public health crisis in a century. But most do not believe that it will be 100 years before another one. The current outbreak of the H5N1 virus, commonly known as 'bird flu,' in cattle and poultry is of particular concern. Related : So far, there have been no reports of human-to-human transmission of H5N1, which is far more deadly than SARS-CoV-2, the virus that causes COVID-19. But 55 people in the United States, mostly poultry and dairy workers, have already been infected. Experts fear that as more people get infected, the virus will have an opportunity to mutate in a way that could make it easily transmissible from one person to another. 'As Donald Trump gets ready to return to the White House on Jan. 20, he must be prepared to tackle one issue immediately: the possibility that the spreading avian flu might mutate to enable human-to-human transmission,' Dr. David Kessler, who ran the Biden administration's COVID vaccine distribution initiative, wrote in a New York Times guest essay. Advertisement In an interview Wednesday, Kessler said he was particularly concerned that longtime officials at agencies like the CDC, NIH and FDA would leave their agencies, depriving the Trump administration of their deep expertise. 'We're not going to get through four years without infectious disease, of that you can be sure,' Kessler said. 'The one thing I've learned is, it never comes at you from where you're expecting. But it will come at you. The most important thing is, on this they need expertise. There is no learning on the job.' Dr. Paul A. Offit, an infectious disease expert and pediatrician at Children's Hospital of Philadelphia, said he was particularly worried about another coronavirus with pandemic potential. The world has experienced three within the past 20 years. SARS (severe acute respiratory syndrome) erupted in China in 2002. MERS (Middle East respiratory syndrome) spread from camels to people in the Arabian Peninsula in 2012. COVID-19 emerged in 2019 in China. Related : Offit said cutting the NIH budget for infectious disease research, as Kennedy has suggested, would be shortsighted. He noted that research into the mRNA technology that enabled the quick production of coronavirus vaccines had begun more than 20 years before the pandemic, with NIH funding. The scientists who pioneered the work, Dr. Katalin Karikó and Dr. Drew Weissman, won a 2023 Nobel Prize. Del Rio said he agreed with Kennedy that more research is needed into chronic disease — but not at the expense of infectious disease. 'This dichotomy between infectious disease and chronic disease is a false dichotomy,' he said. Researchers, public health officials and scientists employed by the government have been reluctant to speak about the president-elect's selections. Dr. Francis Collins, a former head of the NIH who continues to work as a researcher in his genetics lab and who called Bhattacharya a 'fringe epidemiologist,' declined to comment. Advertisement Bhattacharya is one of three lead authors of the Great Barrington Declaration, a manifesto issued in the fall of 2020, before COVID vaccines were available. The manifesto contended that the coronavirus should be allowed to spread among young healthy people who were 'at minimal risk of death,' while prevention efforts were targeted to older people and the vulnerable. The goal, the authors said, was to 'minimize mortality and social harm until we reach herd immunity,' the point at which a virus cannot spread easily from person to person because most people are immune. Public health leaders dismissed it as dangerous and a recipe for millions of American deaths. Related : Instead, experts including Dr. Anthony Fauci, the now-retired head of the Institute for Allergy and Infectious Diseases that is part of NIH, argued that vaccination was the safest path to containing the deadly pathogen. Fauci predicted that it would take until the end of 2021, after a successful vaccination campaign, for the nation to reach herd immunity. In the end, both sides were wrong. Coronavirus deaths in the United States hit a second spike at the end of 2021 and into early 2022, when the omicron variant raced through the population. In the years since then, a number of public health experts have acknowledged that perhaps the lockdowns, masking and school closures went on for too long. 'I would agree that the mitigation strategies were probably wrong, and they were probably there for too long,' said del Rio, the Emory University infectious disease doctor, referring to the masking and lockdowns that Bhattacharya opposed. 'But the Great Barrington Declaration was also wrong, and we need to accept that. Advertisement 'Clearly, during COVID, we all made mistakes," he added, 'and one thing we need to learn is to all be humble so that we don't make them again.' This article originally appeared in
New York Times
27-11-2024
- New York Times
How Will Trump's Covid Contrarians Handle the Next Pandemic?
President-elect Donald J. Trump had already succeeded in rattling the nation's public health and biomedical establishment by the time he announced on Tuesday that he had picked Dr. Jay Bhattacharya to run the National Institutes of Health. But amid growing fears of a deadly bird flu pandemic, perhaps no one was more rattled than experts in infectious disease. Dr. Bhattacharya, a Stanford University medical economist and outspoken opponent of lockdowns, masking, school closures and other Covid-19 mitigation measures, and Mr. Trump's other health picks have one thing in common. They are all considered Covid contrarians whose views raise questions about how they would handle an infectious disease crisis. Robert F. Kennedy Jr., Mr. Trump's choice for health secretary, has said he wants the N.I.H. to focus on chronic disease and 'give infectious disease a break for about eight years.' Dr. Martin Makary, the president-elect's choice to run the Food and Drug Administration, incorrectly predicted in 2021 that the nation was 'racing toward an extremely low level of infection.' Dr. David Weldon, a Republican former congressman who is Mr. Trump's choice to lead the Centers for Disease Control and Prevention, has espoused the debunked theory that thimerosal, a mercury compound in certain vaccines, causes autism. As a congressman, he introduced legislation that would strip the C.D.C. of its role in ensuring vaccine safety, saying the agency had a 'conflict of interest' because it also promotes vaccination. And Dr. Mehmet Oz, the talk show host who has been picked by Mr. Trump to run Medicare and Medicaid, prodded officials in the first Trump administration to give emergency authorization for the malaria drug hydroxychloroquine to treat Covid-19. The F.D.A. later revoked the authorization when studies showed the drug carried risks, including serious heart issues, to coronavirus patients. 'If the worst case scenario happens and we have a serious public health crisis, the body count is going to be enormous because these guys don't have the skills or the will to do anything about it,' said John P. Moore, a virologist and professor at Cornell University's Weill Cornell Medical College. None of Mr. Trump's picks have deep expertise in infectious disease, and each will have to be confirmed by the Senate. 'At the end of the day, if they are confirmed, we are going to have to figure out a way to work with them,' said Dr. Carlos del Rio, an infectious disease expert at Emory University. Mr. Trump's own commitment to pandemic preparedness is unclear. During his first administration, he dismantled a White House office that had been set up by his predecessor, President Barack Obama, to deal with emerging global health threats. Last year, President Biden created a White House Office of Pandemic Preparedness, which Mr. Trump cannot abandon because Congress mandated it by legislation in 2022. There is no way, of course, to predict the arrival of the next pandemic. At the outset of the coronavirus pandemic, experts called it the worst public health crisis in a century. But most do not believe that it will be 100 years before another one. The current outbreak of the H5N1 virus, commonly known as 'bird flu,' in cattle and poultry is of particular concern. So far, there have been no reports of human-to-human transmission of H5N1, which is far more deadly than SARS-CoV-2, the virus that causes Covid-19. But 55 people in the United States, mostly poultry and dairy workers, have already been infected. Experts fear that as more people get infected, the virus will have an opportunity to mutate in a way that could make it easily transmissible from one person to another. 'As Donald Trump gets ready to return to the White House on Jan. 20, he must be prepared to tackle one issue immediately: the possibility that the spreading avian flu might mutate to enable human-to-human transmission,' Dr. David Kessler, who ran the Biden administration's Covid vaccine distribution initiative, wrote in a New York Times guest essay. In an interview on Wednesday, Dr. Kessler said he was particularly concerned that longtime officials at agencies like the C.D.C., N.I.H. and F.D.A. would leave their agencies, depriving the Trump administration of their deep expertise. 'We're not going to get though four years without infectious disease, of that you can be sure,' Dr. Kessler said. 'The one thing I've learned is it never comes at you from where you're expecting. But it will come at you. The most important thing is, on this they need expertise. There is no learning on the job.' Dr. Paul A. Offit, an infectious disease expert and pediatrician at Children's Hospital of Philadelphia, said he was particularly worried about another coronavirus with pandemic potential. The world has experienced three within the past 20 years. SARS (severe acute respiratory syndrome), erupted in China in 2002. MERS (Middle East respiratory syndrome), spread from camels to people in the Arabian Peninsula in 2012. Covid-19 emerged in 2019 in China. Dr. Offit said cutting the N.I.H. budget for infectious disease research, as Mr. Kennedy has suggested, would be shortsighted. He noted that research into the mRNA technology that enabled the quick production of coronavirus vaccines had begun more than 20 years before the pandemic, with N.I.H. funding. The scientists who pioneered the work, Dr. Katalin Karikó and Dr. Drew Weissman, won a 2023 Nobel Prize. Dr. del Rio said he agreed with Mr. Kennedy that more research is needed into chronic disease — but not at the expense of infectious disease. 'This dichotomy between infectious disease and chronic disease is a false dichotomy,' he said. Researchers, public health officials and scientists employed by the government have been reluctant to speak about the president-elect's selections. Dr. Francis Collins, the former head of the National Institutes of Health, who continues to work as a researcher in his genetics lab, and who called Dr. Bhattacharya a 'fringe epidemiologist,' declined to comment. Dr. Bhattacharya is one of three lead authors of the Great Barrington Declaration, a manifesto issued in the fall of 2020, before Covid vaccines were available. The manifesto contended that the coronavirus should be allowed to spread among young healthy people who were 'at minimal risk of death,' while prevention efforts were targeted to older people and the vulnerable. The goal, the authors said, was to 'minimize mortality and social harm until we reach herd immunity,' the point at which a virus cannot spread easily from person to person because most people are immune. Public health leaders dismissed it as dangerous and a recipe for millions of American deaths. Instead, experts including Dr. Anthony S. Fauci, the now-retired head of the Institute for Allergy and Infectious Diseases that is part of N.I.H., argued that vaccination was the safest path to containing the deadly pathogen. Dr. Fauci predicted that it would take until the end of 2021, after a successful vaccination campaign, for the nation to reach herd immunity. In the end, both sides were wrong. Coronavirus deaths in the United States hit a second spike at the end of 2021 and into early 2022, when the Omicron variant raced through the population. In the years since then, a number of public health experts have acknowledged that perhaps the lockdowns and masking and school closures went on for too long. 'I would agree that the mitigation strategies were probably wrong and they were probably there for too long,' said Dr. del Rio, the Emory University infectious disease doctor, referring to the masking and lockdowns that Dr. Bhattacharya opposed. 'But the Great Barrington Declaration was also wrong and we need to accept that. 'Clearly during Covid we all made mistakes," he added, 'and one thing we need to learn is to all be humble so that we don't make them again.'
